Johnson & Johnson's RYBREVANT Combo Shows Near 3.5-Year Survival in Atypical EGFR Lung Cancer
Event summary
- RYBREVANT (amivantamab-vmjw) plus LAZCLUZE (lazertinib) achieved median overall survival of nearly 3.5 years in atypical EGFR-mutated NSCLC patients.
- The Phase 1/1b CHRYSALIS-2 study reported 55% three-year and 46% four-year survival rates in this difficult-to-treat population.
- 41% of patients remained on treatment for two years or longer, demonstrating durable response.
- Results presented at ASCO 2026 reinforce the combination's potential across all EGFR mutations.
The big picture
These results address a significant unmet need in NSCLC treatment, where atypical EGFR mutations historically have poorer outcomes than common mutations. The combination therapy's ability to target multiple disease drivers represents a strategic shift from single-pathway approaches. This success could accelerate adoption of RYBREVANT-based regimens across broader oncology indications.
What we're watching
- Regulatory Expansion
- Whether these results will support expanded approvals for RYBREVANT-based regimens in atypical EGFR mutations.
- Market Differentiation
- How this survival data positions Johnson & Johnson against competitors in targeted lung cancer therapies.
- Commercial Strategy
- The pace at which Johnson & Johnson can convert clinical success into market share gains.
Related topics